OptoPath Coordination : Dr. Véronique Deroche
OptoPath involves 15 scientists from 9 research teams from two research institutes. It therefore concentrates a large number of technical and methodological competences that span all major neurobiological levels (molecules, cells, integrated brain circuits, behaviors).
The Magendie Neurocentre teams brought their expertise to implement new neurobiological tools/procedures (in particular multi-site electrophysiology and optogenetic) and innovative animal models of neuropsychiatric and behavioral disorders allowing investigating formation of declarative memory in mice and humans, transition to drug addiction, PTSD-like behavior and obesity phenotypes.
The Institute of Neurodegenerative Diseases (IMN) includes both preclinical (rodent and primate) and clinical researchers with a clear goal of developing new therapeutic approaches of neurodegenerative disorders by facilitating the translational research from bench to bedside. IMN’s scientists competences include cutting-edge techniques in integrative neuroscience (brain vascular dynamics, in vivo cellular imaging, electrophysiology, functional anatomy), innovative animal models of neuropsychiatric and behavioral disorders.